Oragenics

OGEN55

Penny Stock

$0.32arrow_drop_down2.49%-$0.00

Penny Stock

OGEN55

$0.32

arrow_drop_down2.49%-$0.00

Penny Stock

Performance History

Key Stats
Open	$0.35
Prev. Close	$0.32
EPS	-7.15
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$3.60M
PE Ratio	-

	LOW	HIGH
Day Range	0.27	0.45
52 Week Range	0.27	7.74

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-7.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Oragenics (OGEN)

Oragenics Inc (OGEN) is a company engaged in the development of novel antibiotics and therapeutics to treat infectious diseases. The company focuses on the discovery, development, and commercialization of products targeting the treatment of oral mucositis, a common side effect of cancer therapy. OGEN's lead product candidate, AG013, is an oral rinse formulated with a live biotherapeutic for the prevention and treatment of oral mucositis. The company has conducted Phase 2 clinical trials and is currently preparing for Phase 3 trials. OGEN aims to address the significant unmet medical need in this area and improve the quality of life for cancer patients undergoing intensive chemotherapy and radiation.

In addition to its focus on oral mucositis, Oragenics Inc is also involved in the development of antibiotics for the treatment of infectious diseases. The company's platform technology, TerraCoV2, is designed to generate vaccines and therapeutics against coronaviruses, including COVID-19. OGEN recently entered into a collaboration with the National Research Council of Canada to develop a COVID-19 vaccine candidate. The company is leveraging its expertise in vaccine and antibiotic development to contribute to the global efforts in combating the COVID-19 pandemic.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Kimberly M. Murphy
Headquarters: Tampa
Employees: 6
Exchange: NYSE

Keep an eye on Oragenics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Oragenics 's (OGEN) price per share?

The current price per share for Oragenics (OGEN) is $0.32. The stock has seen a price change of -$0.01 recently, indicating a -2.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Oragenics (OGEN)?

For Oragenics (OGEN), the 52-week high is $7.74, which is 2.31K% from the current price. The 52-week low is $0.27, the current price is 17.9% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Oragenics (OGEN) a growth stock?

Oragenics (OGEN) has shown an average price growth of -6.65% over the past three years. It has received a score of -5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Oragenics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Oragenics (OGEN) stock price performance year to date (YTD)?

As of the latest data, Oragenics (OGEN) has a year-to-date price change of -95.27%. Over the past month, the stock has experienced a price change of -4.7%. Over the last three months, the change has been -71.62%. Over the past six months, the figure is -80.45%. Looking at a longer horizon, the five-year price change stands at -99.02%.

help

Is Oragenics (OGEN) a profitable company?

Oragenics (OGEN) has a net income of -$20.66M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -263.29K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.9M. Furthermore, the EBITDA is -$19.64M.

help

What is the market capitalization of Oragenics (OGEN)?

Oragenics (OGEN) has a market capitalization of $3.61M. The average daily trading volume is 0.37, indicating the stock's liquidity and investor engagement.